Blog
RSS FeedPosted by Michael Wonder on 17 Nov 2022
NICE recommends 3 treatments for COVID-19 in draft guidance
16 November 2022 - Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation. ...
Posted by Michael Wonder on 17 Nov 2022
A tussle over medicines pricing is looming in Britain
15 November 2022 - Agreement to limit the size of the NHS drugs bill under strain. ...
Posted by Michael Wonder on 17 Nov 2022
Ruxolitinib phosphate for the treatment of patients with chronic graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for ...
Posted by Michael Wonder on 17 Nov 2022
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
16 November 2022 - Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer. ...
Posted by Michael Wonder on 17 Nov 2022
New COVID-19 vaccines for eligible Australians
15 November 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on ...
Posted by Michael Wonder on 16 Nov 2022
Ruxolitinib phosphate for the treatment of patients with acute graft versus host disease that is refractory to the use of corticosteroids
16 November 2022 - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib phosphate for ...
Posted by Michael Wonder on 15 Nov 2022
Expansion of access to MenB vaccine urgently needed
15 November 2022 - Meningococcal B is a rare but very serious disease, causing death and serious long-term disabilities. Even when ...
Posted by Michael Wonder on 12 Nov 2022
NSW pharmacists to prescribe the pill, antibiotics in health shake-up
13 November 2022 - Pharmacists will be able to prescribe a range of meds and repeat scripts under a NSW government ...
Posted by Michael Wonder on 11 Nov 2022
Cannabidiol for the treatment of patients with seizures caused by tuberous sclerosis complex
8 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 11 Nov 2022
Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients
10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...
Posted by Michael Wonder on 11 Nov 2022
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting
11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...
Posted by Michael Wonder on 10 Nov 2022
Olaparib for adjuvant treatment of patients with high risk, HER2 negative, BRCA positive early breast cancer after chemotherapy
10 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Nov 2022
Decision to fund long-acting paliperidone for people with schizophrenia and ibrutinib for people with chronic lymphocytic leukaemia
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new medicines. ...
Posted by Michael Wonder on 10 Nov 2022
Decision to fund vedolizumab for inflammatory bowel disease and brentuximab for rare lymphomas
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new treatments: vedolizumab for inflammatory bowel ...